PGN-EDO51
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Duchenne Muscular Dystrophy
Conditions
Duchenne Muscular Dystrophy
Trial Timeline
Jan 3, 2024 → Aug 28, 2025
NCT ID
NCT06079736About PGN-EDO51
PGN-EDO51 is a phase 2 stage product being developed by PepGen for Duchenne Muscular Dystrophy. The current trial status is terminated. This product is registered under clinical trial identifier NCT06079736. Target conditions include Duchenne Muscular Dystrophy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06079736 | Phase 2 | Terminated |
Competing Products
20 competing products in Duchenne Muscular Dystrophy